Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.55 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.51 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.51 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | STAT3 | P40763 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29634161 | 1.00 | SLC7A5 (0.55) | SLC7A5ADRB2ADRB1ADRB3PBRM1 | |
| SCHEMBL27760277 | 0.87 | ADRB2 (0.47) | SLC7A5ADRB2ADRB1ADRB3PBRM1 | |
| SCHEMBL110296 | 0.87 | SLC7A5 (0.58) | SLC7A5STAT3CA12CA1CA2 | |
| Water SCHEMBL28897664 | 0.85 | SLC7A5 (0.56) | SLC7A5STAT3CA12CA1CA2 | |
| SCHEMBL28350987 | 0.85 | SLC7A5 (0.56) | SLC7A5STAT3CA12CA1CA2 | |
| Hydrogen Peroxide SCHEMBL27146001 | 0.85 | SLC7A5 (0.60) | SLC7A5LMNASTAT3CA12CA1 | |
| SCHEMBL8097492 | 0.82 | CA12 (0.49) | SLC7A5LMNASTAT3CA12CA1 | |
| SCHEMBL31188294 | 0.82 | CA12 (0.49) | SLC7A5LMNASTAT3CA12CA1 | |
| SCHEMBL21015802 | 0.82 | SLC7A5 (0.55) | SLC7A5POLBSTAT3CA12CA1 | |
| SCHEMBL27408427 | 0.82 | SLC7A5 (0.55) | SLC7A5STAT3CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 248 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719602-A1 | ANTI-HIV COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-04-08 | — | — | EP | disclosed |
| CN-121494772-A | Preparation method of 3-N-maleimide benzoic acid | 杭州福斯特药业有限公司 | 2026-02-10 | — | — | CN | disclosed |
| US-12491251-B2 | Degraders of cyclin-dependent kinase 7 (CDK7) and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-12-09 | — | — | US | disclosed |
| EP-4010336-B1 | DEGRADERS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2025-04-02 | — | — | EP | disclosed |
| US-20250051375-A1 | ANTI-HIV COMPOUNDS | GILEAD SCIENCES, INC. | 2025-02-13 | — | — | US | disclosed |
| CN-114174281-B | Degradation agent for cyclin-dependent kinase 7 (CDK 7) and use thereof | 达纳-法伯癌症研究公司 | 2025-02-07 | — | — | CN | disclosed |
| US-20250041429-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2025-02-06 | — | — | US | disclosed |
| CN-116348109-B | Piperazine derivative, and preparation method and application thereof | 浙江海正药业股份有限公司 | 2025-01-21 | — | — | CN | disclosed |
| WO-2024249517-A1 | ANTI-HIV COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| EP-4428130-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | Ubix Therapeutics, Inc. (KR) | 2024-09-11 | — | — | EP | disclosed |
| EP-0776892-A1 | THIENYLAZOLE COMPOUND AND THIENOTRIAZOLODIAZEPINE COMPOUND | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1997-06-04 | — | — | EP | disclosed |
| EP-0756602-A1 | CCK OR GASTRIN MODULATING 5-HETEROCYCLIC-1,5-BENZODIAZEPINES | GLAXO WELLCOME INC. (US) | 1997-02-05 | — | — | EP | disclosed |
| EP-0755384-A1 | CCK OR GASTRIN MODULATING 1,5 BENZODIAZEPINES DERIVATIVES | GLAXO WELLCOME INC. (US) | 1997-01-29 | — | — | EP | disclosed |
| EP-0755394-A1 | A METHOD OF INDUCING CHOLECYSTOKININ AGONIST ACTIVITY USING 1,4-BENZODIAZEPINE COMPOUNDS | GLAXO WELLCOME INC. (US) | 1997-01-29 | — | — | EP | disclosed |
| US-5585376-A | 1,5-benzodiazepine derivatives having CCK and/or gastrin antagonistic activity | GLAXO WELLCOME INC. (US) | 1996-12-17 | — | — | US | disclosed |
| EP-0694040-A1 | 1,5 BENZODIAZEPINE DERIVATIVES HAVING CCK AND/OR GASTRIN ANTAGONISTIC ACTIVITY | GLAXO WELLCOME INC. (US) | 1996-01-31 | — | — | EP | disclosed |
| WO-1995028399-A1 | A METHOD OF INDUCING CHOLECYSTOKININ AGONIST ACTIVITY USING 1,4-BENZODIAZEPINE COMPOUNDS | GLAXO WELLCOME INC. (US) | 1995-10-26 | — | — | WO | disclosed |
| WO-1995028391-A1 | CCK OR GASTRIN MODULATING 1,5 BENZODIAZEPINES DERIVATIVES | GLAXO WELLCOME INC. (US) | 1995-10-26 | — | — | WO | disclosed |
| WO-1995028419-A1 | CCK OR GASTRIN MODULATING 5-HETEROCYCLIC-1,5-BENZODIAZEPINES | GLAXO WELLCOME INC. (US) | 1995-10-26 | — | — | WO | disclosed |
| WO-1994024151-A1 | 1,5 BENZODIAZEPINE DERIVATIVES HAVING CCK AND/OR GASTRIN ANTAGONISTIC ACTIVITY | GLAXO INC. (US) | 1994-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12491251-B2 | Degraders of cyclin-dependent kinase 7 (CDK7) and uses thereof | CDK7, CDK8, CDK17 | SLC7A5 4548/4885ADRB2 4359/4885ADRB1 4240/4885 |
| US-20250051375-A1 | ANTI-HIV COMPOUNDS | CCR5, CD4, NFATC1 | SLC7A5 628/4885ADRB2 2346/4885ADRB1 1328/4885 |
| US-20250041429-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | BTK, LYN, SYK | SLC7A5 3337/4885ADRB2 4633/4885ADRB1 4584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.